Leigh Perreault

Aug 8, 2023 | jamanetwork.com | Mayer B. Davidson |Charles R. Drew |Justin B. Echouffo-Tcheugui |Leigh Perreault

To the Editor A recent Review1 concluded that prediabetes is associated with an increased risk of cardiovascular disease events.

Aug 8, 2023 | jamanetwork.com | Sam Dagogo-Jack |Justin B. Echouffo-Tcheugui |Leigh Perreault |Linong Ji

In Reply In his Letter about our recent Review article,1 Dr Entezari-Maleki suggests that SGLT2 inhibitors be considered in the treatment of prediabetes while noting that no drug treatment has yet been approved by the FDA for people with prediabetes. Clearly, the glucosuric effect of SGLT2 inhibitors decreases blood glucose levels in people with hyperglycemia. Additionally, the weight loss induced by SGLT2 inhibitors would be beneficial in people with prediabetes who have overweight or obesity.

Jul 11, 2023 | medscape.com | Leigh Perreault

The National Diabetes Data Group and World Health Organization first introduced formal diagnostic criteria for diabetes in 1979-1980. Thereafter, cross-sectional studies showed microvascular disease (MVD) and cardiovascular disease (CVD) to be higher in patients with fasting plasma glucose (FPG) levels ≥ 140z mg/dL and/or a 2-hour post-challenge glucose ≥ 200 mg/dL.